VIIV HEALTHCARE PTY LTD

GSK presents abstracts on RSV vaccine safety, immunogenicity, and disease burden in older adults, along with studies on pertussis, meningococcal, and herpes zoster vaccines. Also included are abstracts on GSK's infectious disease medicines, focusing on urinary tract infections and antimicrobial resistance, and ViiV Healthcare's portfolio, featuring HIV treatment and prevention with long-acting injectables.

ViiV Healthcare plans to triple its HIV prevention therapy supply at not-for-profit prices in low- and middle-income countries by 2026, committing to 2 million doses of long-acting cabotegravir for pre-exposure prophylaxis. This move aims to accelerate HIV prevention in resource-limited, high-burden countries.

ViiV Healthcare's CEO, Deborah Waterhouse, highlights the significance of the long-acting PrEP, CAB LA, in addressing HIV in high-risk populations, particularly young women and girls in Sub-Saharan Africa. The roll-out of CAB LA for PrEP is rapidly expanding in Sub-Saharan Africa and lower-income countries, with 79% of approvals in low- and middle-income countries. ViiV provides CAB LA at a not-for-profit price, facilitated by partnerships with PEPFAR and The Global Fund, and aims to ensure sustainable access through licensing agreements with the Medicines Patent Pool.

Halozyme Therapeutics announces argenx has nominated four new targets for ENHANZE® drug delivery tech, bringing the total to six, including FcRn. argenx to pay Halozyme $30 million upfront and potential future milestone payments up to $85 million per target.

ViiV Healthcare defends its rapid rollout of CAB LA for PrEP in sub-Saharan Africa, emphasizing its commitment to providing access to HIV prevention medicines. The company highlights its accomplishments, including negotiating a voluntary license with the Medicines Patent Pool and delivering over 1 million doses to lower- and middle-income countries by 2025. ViiV also stresses its focus on clinical trial diversity and support for high-risk populations, such as adolescent girls and young women in sub-Saharan Africa.

Brands2Life appoints Isabelle Scali as head of pharma to lead new service aiding pharmaceutical companies in navigating health and technology, aiming for more agile and creative healthcare communications.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.